• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>PIMCO Municipal Income II

PIMCO Municipal Income II

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

    FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

  2. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

  3. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

©2017 Morningstar Advisor. All right reserved.